BeiGene seeks to the join I-O and chemo party in massive market

25 July 2018
2019_biotech_test_vial_discovery_big

Chinese biotech BeiGene (Nasdaq: BGNE) has started a trial that could signal the suitability of its immune checkpoint inhibitor tislelizumab – in combination with chemotherapy – for a massive patient group.

The first patient has been dosed in a Phase III trial of this combination to check its suitability as a potential first-line treatment in Chinese patients with stage three or four non-squamous non-small cell lung cancer (NSCLC).

In the trial, tislelizumab is being added to platinum plus pemetrexed chemotherapy, the current global standard of care in first-line treatment of patients with advanced stage non-squamous NSCLC.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology